Drug safety test halted early
NCT ID NCT05126329
Summary
This study aimed to understand how a single dose of the experimental drug amcenestrant is processed by the body in women with mild to moderate liver problems, compared to women with normal liver function. It was a small, early-stage safety and measurement study that was terminated. The goal was to gather data on how the drug moves through and stays in the body of people with different liver health.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATIC FUNCTION ABNORMAL are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Investigational Site Number :2760001
Kiel, 24105, Germany
-
Investigational Site Number :4100001
Seoul, Seoul-teukbyeolsi, 03080, South Korea
-
Investigational site number :4100002
Cheongju-si, 28644, South Korea
Conditions
Explore the condition pages connected to this study.